Curio Wealth’s Neurocrine Biosciences NBIX Stock Holding History

Curio Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2	Closed	-$263	–	756
2026 Q1	$263	Buy	+2	New	+$265	﹤0.01%	677

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Curio Wealth's NBIX Position: Q2 2026 in Review

Curio Wealth sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 2 shares — an estimated $263 sold.

Curio Wealth first reported a position in NBIX in Q1 2026 and held it in 1 quarter. The position peaked at $263 in Q1 2026. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Curio Wealth reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
Curio Wealth sold 2 Neurocrine Biosciences shares in Q2 2026, an estimated $263.
Curio Wealth first reported a position in Neurocrine Biosciences in Q1 2026 and held it in 1 quarter.
Curio Wealth's Neurocrine Biosciences position peaked at $263 in Q1 2026.
781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Curio Wealth's 13F filing for Q2 2026, filed 7 Aug 2026.